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Analysis of predicted coronary heart disease risk in
England based on Framingham study risk appraisal
models published in 1991 and 2000
Kiran Nanchahal, John R Duncan, Paul N Durrington, Rodney T Jackson
In 2000 the UK government launched the national
service framework for coronary heart disease, setting
national standards for improving prevention, diagno›
sis, and treatment. In agreement with recent recom›
mendations on preventing coronary heart disease1 and
managing hypertension,2 this programme includes use
of coronary risk appraisal models from the Framing›
ham study published in 19913 to help identify patients
eligible for drug treatment. These models were
updated in 2000,4 incorporating further follow up and
additional risk factors. We compare the predicted risks
calculated using the two models and assess the
implications for preventing heart disease.
Methods and results
The health survey for England is an annual,
nationwide, household based, cross sectional survey of
a representative sample of the population. We used the
1998 survey data for 5518 (62.3% of 8852) participants
aged 35›74 with complete information on factors
needed for assessment of coronary disease risk, after
exclusion of 738 (7.7% of 9590) participants reporting
angina, heart attack, or stroke diagnosed by a doctor.5
The 2000 models allow calculation of risk over a
period of four years,4 whereas the 1991 models permit
estimation of risk over 4›12 years.3 We estimated the 10
year and four year probabilities of developing heart
disease predicted using the 1991 equations and the
four year risk predicted using the 2000 equations.
Summary statistics for four year coronary disease
risk per 100 population based on the 1991 and 2000
models within a range of risk categories show that both
models generally produce similar distributions (table).
Although substantial statistical agreement exists
between classification of participants into risk catego›
ries based on the two models, participants within each
category based on the 1991 models were distributed
across a wide range of risk categories based on the
2000 models.
Comment
Although population distributions of coronary risk
calculated with the two models are generally similar, a
significant number of people meeting criteria for drug
treatment on the basis of the 1991 models would not
meet the equivalent criteria on the basis of the 2000
models. Current UK guidelines generally recommend
offering drug treatment for hypertension or hypercho›
lesterolaemia to patients with a 10 year risk >15%.1 2
We used a 5% risk of a coronary event in four years as
being equivalent to a 10 year risk of 15%, rather than
6% over four years, because risk increases exponen›
tially rather than linearly with age. Had we used 6%, the
discrepancy between the 1991 and 2000 models would
have been even greater.
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Our study confirms that risk of coronary disease in
Britain is high. On the basis of the 1991 risk appraisal
models, approximately 32% of men and 7% of women
aged 35›74 in England are at >15% risk of developing
heart disease in the next 10 years. The 2000 models
give figures for a four year risk >5% of 29% for men
and 6% for women. Although only 1›2% of men and
women ineligible for drug treatment under current
criteria would be eligible if the 2000 models were
used, 20% of men and 43% of women currently
recommended drug treatment would not be eligible if
their four year risk based on the updated models was
used. Sensitivity and specificity for the 1991 risk
appraisal models would be 97.6% and 90.0% for men
and 79.7% and 96.0% for women, considering the
updated models to provide the most up to date assess›
ment of coronary disease risk for asymptomatic men
and women. Although thresholds for drug treatment
are somewhat arbitrary and depend to a large degree
on the resources available, we recommend that these
findings are taken into account when guidelines for
coronary heart disease prevention are updated in
accordance with emerging scientific evidence for
statin treatment and management of mild hyper›
tension.
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Number of participants and mean (SD) risk in four year predicted risk categories based on coronary heart disease risk appraisal
models from the Framingham study published in 19913 and 20004
1991 models 2000 models: risk category*
Risk
category* Mean (SD) <2 >2, <4 >4, <5 >5, <6 >6, <8 >8, <10 >10 All %
Men
Mean (SD) N/A 1.2 (0.43) 2.9 (0.58) 4.5 (0.29) 5.5 (0.30) 6.9 (0.55) 8.9 (0.58) 15.8 (6.57) 4.4 (4.53) N/A
<2 1.0 (0.52) 812 61 0 0 0 0 0 873 34.0
>2, <4 3.0 (0.58) 74 504 21 1 0 0 0 600 23.3
>4, <5 4.5 (0.29) 0 118 57 12 5 0 0 192 7.5
>5, <6 5.5 (0.29) 0 53 76 53 15 0 0 197 7.7
>6, <8 6.9 (0.56) 0 0 53 77 89 20 2 241 9.4
>8, <10 9.0 (0.55) 0 0 0 14 108 41 14 177 6.9
>10 13.9 (3.86) 0 0 0 0 21 70 200 291 11.3
All 4.6 (4.31) 886 736 207 157 238 131 216 2571 100
% N/A 34.5 28.6 8.0 6.1 9.3 5.1 8.4 100 N/A
Women
Mean (SD) N/A 0.8 (0.53) 2.8 (0.57) 4.5 (0.27) 5.5 (0.30) 6.8 (0.57) 8.9 (0.51) 13.9 (2.81) 1.8 (2.01) N/A
<2 0.7 (0.56) 1831 125 4 2 2 0 0 1964 66.6
>2, <4 2.8 (0.56) 228 294 34 10 3 0 0 569 19.3
>4, <5 4.5 (0.28) 9 102 27 12 7 0 1 158 5.4
>5, <6 5.4 (0.29) 2 37 17 13 4 1 0 74 2.5
>6, <8 6.8 (0.56) 1 17 29 23 27 6 2 105 3.6
>8, <10 8.8 (0.60) 0 1 6 7 9 9 6 38 1.3
>10 12.3 (1.92) 0 1 0 3 9 10 16 39 1.3
All 1.9 (2.25) 2071 577 117 70 61 26 25 2947 100
% N/A 70.3 19.6 4.0 2.4 2.1 0.9 0.8 100 N/A
Weighted ‚ (95% CI): men 0.83 (0.82 to 0.84); women 0.67 (0.65 to 0.69). N/A=not applicable. *Number of coronary heart disease events per 100 population.
Corrections and clarifications
Minerva
A keyboard slip seems to have accounted for
Minerva attributing a study to a US rather than UK
hospital (20 April, p 986). The study was about
physical illness in patients referred to psychiatric
clinics and was reported in Acta Psychiatrica
Scandinavica.
Science, medicine, and the future: New vaccine
development
Because of an editorial oversight (mistaking one
competing interest form for another), this article by
Gregory A Poland and colleagues (1 June, pp
1315›9) did not include Dr Poland’s declaration
that he had performed a trial of a DNA vaccine
funded by Powderject Vaccines.
Unexplained differences in sex ratios at birth in Europe
and North America
In the table accompanying this Research Pointer by
Victor Grech and colleagues (27 April, pp 1010›1),
readers may have been surprised to see that
Denmark and Finland seemed to have exactly the
same numbers of female and total live births. This
was in fact an error, which arose during editing and
was not picked up on the proofs. The figures for
Finland were correct, but for Denmark the number
of female live births are 1 588 490 and total live
births 3 269 412.
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